Cornea

Investigators find that oestradiol drops can ease signs and symptoms for 3 months.

Glaukos Corp’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.

According to Dr Claudia Perez-Straziota, persistent epithelial defects do not have to live up to their name—they can be healed.

Loteprednol etabonate suspension 0.25% demonstrates anti-inflammatory action and produces significant improvement in conjunctival hyperaemia and ocular discomfort.

Intracanicular insert is the first physician-administered, preservative-free method.

Corneal aberrations may occur more frequently than is generally appreciated, and they affect the visual outcomes following cataract surgery. Small-aperture optics provide a solution for a large category of patients who are otherwise not well served by complex IOLs.

Dr Preeya Gupta walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

Partial topography-guided surface ablation, combined with corneal collagen crosslinking when visual acuity is still quite good, optimises prognosis for the patient with keratoconus.

Impairment of corneal sensory innervation causes reduction of both protective reflexes and trophic neuromodulators that are essential for the vitality, metabolism, and wound healing of the ocular surface.

Patients can benefit from short-term, on-label treatment with a novel loteprednol formulation.

Corneal collagen crosslinking was found to stabilise the cornea, and in some cases improve vision and keratometry values, in children and young adults.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall pointed out that an epidemiologic analysis of malignant ocular surface tumours found significant differences in geographic prevalence rates in the United States.

Dr Shady Awwad in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and instead contributes to development of more corneal haze.

Evidence shows that higher corneal sensitivity may be associated with pain phenotypes, such as the presence of chronic pain involving the trigeminal system.

New serological biomarkers could characterise Sjögren’s syndrome better than traditionally used autoantibodies.

Ex vivo experiment identifies potential benefit for supplementary oxygen.

Exploring subtleties helps ophthalmologists understand postoperative surprises.

Scanning laser ophthalmoscopy offers improved view of posterior segment.

A 48-year-old male patient presented to an ophthalmic emergency department with what was described as progressive bilateral corneal melting 5 weeks after he received the first dose of a COVID-19 vaccine.

Newly developed acrylic implant provides option for patients with endothelial dysfunction.

One ophthalmologist provides her pearls for managing cases of prolapsed iris and reconstructing it following trauma.

It is widely accepted that patient selection is the key to success with premium IOLs. However, with care, premium IOLs can be implemented in challenging cases.

Customised myopic LASIK using automated ray tracing optimisation has the potential to offer improved and more predictable outcomes, a study shows.

Studies show that corneal crosslinking could be a beneficial treatment in paediatric patients with keratoconus.

Topography-guided treatments for irregular corneas can improve patients’ best corrected visual acuity. The technique is easy to plan and perform, supported by software to do the calculations.

Topography-guided PRK, with or without the addition of corneal crosslinking, can improve visual acuity and quality in patients with keratoconus.

Cyclosporine for dry eye disease appears to be efficacious at all levels and the choice of which formulation to use usually depends on tolerability and affordability. Tolerability hinges primarily on the vehicle, which varies among different products.

In recent years, ophthalmologists have seen several new therapeutics for the treatment of dry eye disease.